Poster: Shi, Y.;  Zhang, Q.;  Han, X.;  Song, Y.;  Qin, Y.;  Hong, X.;  Ke, X.;  Feng, J.;  Wang, D.;  Li, W.;  Su, H.;  Zhang, Y.;  Zhang, H.;  Yang, J.;  Liu, L.;  Zhang, X.;  Liu, E.;  Jiang, W.;  Liu, S.; Luk, A., 286PFirst china-manufactured proposed rituximab biosimilar met primary efficacy and safety endpoints in CD20-positive diffuse large B-cell lymphoma (generics). Annals of Oncology 2018, 29 (suppl_9), mdy437.005-mdy437.005.

Poster: Xu, B.; Zhang, Q.; Sun, T.; Li, W.; Teng, Y.; Hu, X.; Bondarenko, I.; Adamchuk, H.; Li, Y.; Shan, B.; Cheng, J.; Peng, T.; Wang, X.; Chen, Y.; Jiang, W.; Liu, S.; Zhang, X.; Liu, E.; Luk, A.; Wang, Q., LBA6First China-manufactured trastuzumab biosimilar HLX02 global phase III trial met primary endpoint in breast cancer. Annals of Oncology 2019, 30 (suppl_9), mdy446.005.

Manuscript: Xu, Y.;  Xie, L.;  Zhang, E.;  Gao, W.;  Wang, L.;  Cao, Y.;  Xie, M. H.;  Jiang, W.; Liu, S., Physicochemical and functional assessments demonstrating analytical similarity between rituximab biosimilar HLX01 and the MabThera®. mAbs 2019, 1-15.